248 lines
8.7 KiB
Markdown
248 lines
8.7 KiB
Markdown
# Cell Press Summary, Highlights, and eTOC Examples
|
||
|
||
Examples of Cell Press-specific elements including Summary (abstract), Highlights, and eTOC blurb.
|
||
|
||
---
|
||
|
||
## Complete Example 1: Senescence and Aging
|
||
|
||
### Summary (150 words max)
|
||
|
||
```
|
||
Cellular senescence is a stress response that prevents damaged cell
|
||
proliferation but can drive tissue dysfunction through the senescence-
|
||
associated secretory phenotype (SASP). How senescent cells resist
|
||
apoptosis despite expressing pro-apoptotic p53 has remained unclear.
|
||
Here, we identify FOXO4 as a pivotal mediator of senescent cell viability.
|
||
FOXO4 is highly expressed in senescent cells and directly interacts with
|
||
p53, retaining it in the nucleus and preventing p53-mediated apoptosis.
|
||
A cell-permeable peptide that disrupts FOXO4-p53 interaction selectively
|
||
induces p53 nuclear exclusion and apoptosis in senescent cells without
|
||
affecting proliferating cells. In vivo, this FOXO4 peptide neutralizes
|
||
doxorubicin-induced senescent cells and restores fitness, fur density,
|
||
and renal function in naturally aged mice. These findings establish
|
||
FOXO4-mediated p53 sequestration as a senescence-specific survival
|
||
pathway and demonstrate the therapeutic potential of targeted senescent
|
||
cell elimination.
|
||
```
|
||
|
||
### Highlights (≤85 characters each)
|
||
|
||
```
|
||
• FOXO4 is selectively upregulated in senescent cells and binds p53
|
||
|
||
• FOXO4-p53 interaction retains p53 in the nucleus, preventing apoptosis
|
||
|
||
• A FOXO4-targeting peptide induces apoptosis specifically in senescent cells
|
||
|
||
• FOXO4 peptide treatment restores fitness and organ function in aged mice
|
||
```
|
||
|
||
### eTOC Blurb (30-50 words)
|
||
|
||
```
|
||
Baar et al. identify FOXO4 as a critical mediator of senescent cell survival
|
||
through p53 sequestration. A peptide disrupting FOXO4-p53 interaction
|
||
selectively eliminates senescent cells and restores tissue function in
|
||
aged mice, establishing proof-of-concept for targeted senolytic therapy.
|
||
```
|
||
|
||
### In Brief (1 sentence)
|
||
|
||
```
|
||
A FOXO4-targeting peptide selectively eliminates senescent cells by
|
||
releasing p53, restoring tissue function in aged mice.
|
||
```
|
||
|
||
---
|
||
|
||
## Complete Example 2: Genome Organization
|
||
|
||
### Summary (150 words max)
|
||
|
||
```
|
||
The three-dimensional organization of chromosomes within the nucleus
|
||
influences gene expression, DNA replication, and genome stability.
|
||
Phase separation has emerged as a potential mechanism for organizing
|
||
nuclear contents, but whether condensates can shape chromosome
|
||
structure in vivo remains unknown. Here, we show that the transcriptional
|
||
coactivator BRD4 forms liquid-like condensates at super-enhancers that
|
||
organize associated chromatin into hub structures. Optogenetic induction
|
||
of BRD4 condensates is sufficient to remodel chromosome topology and
|
||
activate transcription within minutes. Conversely, disruption of BRD4
|
||
condensates with the small molecule JQ1 dissolves chromatin hubs and
|
||
rapidly silences super-enhancer-controlled genes. Single-molecule
|
||
tracking reveals that condensate formation increases the local
|
||
concentration of transcription machinery 100-fold, explaining the
|
||
transcriptional potency of super-enhancers. These results establish
|
||
phase separation as a mechanism for chromatin organization and
|
||
transcriptional control with implications for understanding and
|
||
targeting oncogenic super-enhancers.
|
||
```
|
||
|
||
### Highlights
|
||
|
||
```
|
||
• BRD4 forms liquid condensates at super-enhancers in living cells
|
||
|
||
• BRD4 condensates organize chromatin into transcriptionally active hubs
|
||
|
||
• Optogenetic condensate induction rapidly remodels chromatin topology
|
||
|
||
• Condensates concentrate transcription machinery 100-fold locally
|
||
```
|
||
|
||
### eTOC Blurb
|
||
|
||
```
|
||
Sabari et al. demonstrate that BRD4 forms phase-separated condensates
|
||
at super-enhancers that organize chromatin into hub structures and
|
||
concentrate transcription machinery. Optogenetic manipulation reveals
|
||
that condensate formation directly drives chromatin remodeling and
|
||
transcriptional activation.
|
||
```
|
||
|
||
---
|
||
|
||
## Complete Example 3: Metabolism and Immunity
|
||
|
||
### Summary (150 words max)
|
||
|
||
```
|
||
Immune cells undergo dramatic metabolic reprogramming upon activation,
|
||
switching from oxidative phosphorylation to aerobic glycolysis. This
|
||
metabolic shift is thought to support the biosynthetic demands of
|
||
rapid proliferation, but whether specific metabolites directly regulate
|
||
immune cell function remains largely unexplored. Here, we show that
|
||
the glycolytic metabolite phosphoenolpyruvate (PEP) sustains T cell
|
||
receptor signaling by inhibiting sarco/endoplasmic reticulum Ca²⁺-ATPase
|
||
(SERCA) activity. PEP accumulates in activated T cells and directly
|
||
binds SERCA, preventing calcium reuptake and prolonging store-operated
|
||
calcium entry. Genetic or pharmacological enhancement of PEP levels
|
||
augments T cell effector function and anti-tumor immunity in vivo.
|
||
Conversely, tumor-derived lactate suppresses PEP levels and impairs
|
||
T cell calcium signaling, contributing to tumor immune evasion. These
|
||
findings reveal an unexpected signaling role for a glycolytic
|
||
intermediate and suggest metabolic strategies to enhance T cell
|
||
responses in cancer immunotherapy.
|
||
```
|
||
|
||
### Highlights
|
||
|
||
```
|
||
• Phosphoenolpyruvate (PEP) accumulates during T cell activation
|
||
|
||
• PEP directly binds and inhibits SERCA to sustain calcium signaling
|
||
|
||
• Enhancing PEP levels augments anti-tumor T cell immunity
|
||
|
||
• Tumor lactate suppresses T cell PEP levels and calcium signaling
|
||
```
|
||
|
||
### eTOC Blurb
|
||
|
||
```
|
||
Ho et al. discover that the glycolytic metabolite phosphoenolpyruvate
|
||
directly regulates T cell calcium signaling by inhibiting SERCA. This
|
||
metabolic-signaling link is exploited by tumors through lactate
|
||
secretion and offers new targets for cancer immunotherapy.
|
||
```
|
||
|
||
---
|
||
|
||
## Graphical Abstract Description Examples
|
||
|
||
### For Senescence Paper
|
||
|
||
```
|
||
"Graphical abstract for Cell paper on FOXO4 and senescence:
|
||
|
||
Left panel: Senescent cell (enlarged, irregular shape) with FOXO4 (blue
|
||
oval) binding p53 (green oval) in nucleus, preventing apoptosis. Label:
|
||
'FOXO4 sequesters p53 → Senescent cell survival'
|
||
|
||
Center panel: Same senescent cell with FOXO4 peptide (red wedge)
|
||
disrupting FOXO4-p53 interaction. p53 moves to mitochondria (orange
|
||
organelles). Label: 'FOXO4 peptide disrupts interaction'
|
||
|
||
Right panel: Senescent cell undergoing apoptosis (fragmenting). Label:
|
||
'Selective senescent cell death'
|
||
|
||
Bottom: Aged mouse (grey, hunched) → Treatment arrow → Rejuvenated mouse
|
||
(brown, active). Label: 'Restored fitness in aged mice'
|
||
|
||
Color scheme: Blue for FOXO4, green for p53, red for peptide, grey
|
||
background for cells."
|
||
```
|
||
|
||
### For Chromatin Paper
|
||
|
||
```
|
||
"Graphical abstract for Cell paper on BRD4 condensates:
|
||
|
||
Top row: Diagram showing BRD4 molecules (purple dots) clustering at
|
||
super-enhancer (yellow region on DNA strand), forming condensate
|
||
(purple droplet). Transcription factors (orange, green, blue small
|
||
circles) accumulate inside condensate.
|
||
|
||
Middle: Chromatin fibers (grey) being pulled into hub structure around
|
||
condensate. Arrow showing '100× local concentration increase'
|
||
|
||
Bottom: Two panels - Left shows 'JQ1' treatment dissolving condensate
|
||
and chromatin hub dispersing. Right shows 'Optogenetic activation'
|
||
creating new condensate with chromatin reorganization. Gene expression
|
||
indicators (up arrow, down arrow) for each condition."
|
||
```
|
||
|
||
---
|
||
|
||
## Writing Tips for Cell Elements
|
||
|
||
### Summary Tips
|
||
|
||
1. **First sentence**: Establish the biological context
|
||
2. **Second sentence**: State what was unknown (the gap)
|
||
3. **"Here, we show/identify/demonstrate"**: Clear transition to your work
|
||
4. **Middle sentences**: Key findings with mechanism
|
||
5. **Final sentence**: Significance and implications
|
||
|
||
### Highlights Tips
|
||
|
||
- **Start with a noun or verb**: "FOXO4 forms..." or "Activation of..."
|
||
- **One finding per bullet**: Don't combine multiple points
|
||
- **Be specific**: Include the protein/gene/pathway name
|
||
- **Check character count**: Strictly ≤85 characters including spaces
|
||
- **Cover different findings**: Don't repeat the same point
|
||
|
||
### eTOC Blurb Tips
|
||
|
||
- **Start with author names**: "Smith et al. show that..."
|
||
- **One or two sentences only**: Keep it punchy
|
||
- **Include the key mechanism**: Not just the finding
|
||
- **End with significance**: Why readers should care
|
||
|
||
---
|
||
|
||
## Character Counting for Highlights
|
||
|
||
Use this to check your highlights:
|
||
|
||
```
|
||
• This highlight is exactly 52 characters long including sp
|
||
↑ Count: 52 characters ✓ (under 85)
|
||
|
||
• This highlight is getting close to the maximum allowed character limit
|
||
↑ Count: 73 characters ✓ (under 85)
|
||
|
||
• This highlight demonstrates what happens when you try to include way too much info
|
||
↑ Count: 88 characters ✗ (over 85 - need to shorten)
|
||
```
|
||
|
||
---
|
||
|
||
## See Also
|
||
|
||
- `cell_press_style.md` - Comprehensive Cell Press writing guide
|
||
- `nature_abstract_examples.md` - Compare with Nature abstract style
|
||
|